Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187-8502, Japan; Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187-8502, Japan; Medical Genome Center, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan.
Psychiatry Res. 2017 Aug;254:244-250. doi: 10.1016/j.psychres.2017.04.060. Epub 2017 Apr 27.
G72 is a modulator of D-amino acid oxidase, the enzyme that degrades D-serine, an amino acid that plays a critical role in glutamate neurotransmission, and has been implicated in psychiatric disorders. The aim of this study was to examine whether plasma or cerebrospinal fluid (CSF) G72 protein levels were altered in either schizophrenia or major depressive disorder (MDD) and whether any correlation between G72 levels and disease severity existed. Initially, 27 schizophrenic patients, 26 MDD patients, and 27 healthy controls matched for age, sex, and ethnicity were enrolled. Compared to those of controls, plasma or CSF G72 levels were not significantly different in patients with schizophrenia or MDD. Although we found a significant positive correlation between plasma G72 levels and a positive symptoms score on the positive and negative syndrome scale (PANSS), this was not replicated in the second study (40 schizophrenic patients). CSF G72 levels showed no significant correlation with PANSS scores. In MDD, neither plasma nor CSF G72 levels correlated significantly with depression severity. Since severity of our patients were relatively mild, further investigations in a large number of subjects including drug-free patients, younger patients, and more severely affected patients are warranted.
G72 是 D-氨基酸氧化酶的调节剂,该酶可降解 D-丝氨酸,D-丝氨酸是谷氨酸能神经传递中起关键作用的氨基酸,与精神疾病有关。本研究旨在探讨血浆或脑脊液(CSF)中 G72 蛋白水平是否在精神分裂症或重度抑郁症(MDD)中发生改变,以及 G72 水平与疾病严重程度之间是否存在相关性。最初,招募了 27 名精神分裂症患者、26 名 MDD 患者和 27 名年龄、性别和种族匹配的健康对照者。与对照组相比,精神分裂症或 MDD 患者的血浆或 CSF G72 水平无显著差异。尽管我们发现血浆 G72 水平与阳性和阴性症状量表(PANSS)上的阳性症状评分呈显著正相关,但在第二项研究(40 名精神分裂症患者)中未得到复制。CSF G72 水平与 PANSS 评分无显著相关性。在 MDD 中,血浆和 CSF G72 水平与抑郁严重程度均无显著相关性。由于我们患者的严重程度相对较轻,因此需要在包括无药物治疗患者、年轻患者和病情更严重的患者在内的大量患者中进一步进行研究。